AMIRAJU
LIVE

Serial Number

79438869

Owner

AMI PHARM CO., LTD.

Filing Date

Sep 24, 2025

Add to watchlist:

No watchlists yet
View on USPTO

AMIRAJU Trademark

Serial Number: 79438869

AMIRAJU is a trademark filed by AMI PHARM CO., LTD. on September 24, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

AMI PHARM CO., LTD.

#907, 9th fl., 545, Dunchon-daero,

Entity Type: 03

Trademark Details

Filing Date

September 24, 2025

Registration Date

Not Registered

Goods & Services

Injectable preparations for treating and/or reducing and/or inhibiting of obesity; injectable preparations for medical purposes; injectable medicinal preparations; injectable preparations for improving and/or treating of skin; injectable preparations for diet medical purposes; injectable preparations for therapeutic use; injectable preparations for abdominal fat reduction; medicinal preparations for reducing localized fat deposits; medicinal preparations for treating and/or reducing and/or inhibiting of obesity; medicinal preparations for abdominal fat reduction; medicinal preparations for the treatment of cellulite; medicinal preparations for submental fat reduction; medicinal preparations for reducing localized upper arm fat deposits; medicinal preparations for the treatment of submental fat; filled syringes for medical purposes; pharmaceutical agents affecting metabolism; medical preparations for slimming purposes; pharmaceutical preparations for the treatment and prevention of obesity.

Filing History

REFUSAL PROCESSED BY IB
Mar 19, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 2, 2026 RFCS
REFUSAL PROCESSED BY MPU
Mar 2, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 3, 2026 RFCR
NON-FINAL ACTION WRITTEN
Feb 2, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 30, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 12, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 12, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 11, 2025 REPR